QNTM
Quantum BioPharma Ltd.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-59/100
Last price
3.07
▼ 0.02 (0.65%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.01
Prev close
3.09
Day high
3.11
Day low
3.03
Volume
48.80K
Market cap
$19.74M
P/E (TTM)
—
52W range
2.07 – 17.50
Day trading desk
Gap from prior close
-2.57%
Prior close 3.09
VWAP
3.08
-0.16% from price
Relative volume
0.24×
Quiet session
Session range
3.32%
3.01 – 3.11
Position in range
60%
Mid range
ATR (14D)
0.29
9.58% of price
Prior day high
3.39
PDH
Prior day low
3.05
PDL
Bid / ask spread
—
Quote not published
Session volume
48.60K
Avg 204.28K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-14.72%
-16.3%
1M
-6.69%
-7.8%
3M
-9.97%
-13.0%
6M
-16.58%
-31.1%
YTD
-57.95%
-71.5%
1Y
-82.83%
-98.1%
3Y
-95.93%
-177.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on QNTM open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
679.19K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 8, 26 | Carroll (Donal) Director of Issuer |
SELL | 1.85K | $7.17K | Direct |
| Apr 7, 26 | Carroll (Donal) Director of Issuer |
SELL | 9.00K | $32.86K | Direct |
| Apr 6, 26 | Carroll (Donal) Director of Issuer |
SELL | 3.95K | $14.51K | Direct |
| Apr 1, 26 | Carroll (Donal) Director of Issuer |
SELL | 100.00K | $535.50K | Direct |
| Mar 20, 26 | Carroll (Donal) Director of Issuer |
BUY | 100.00K | $218.60K | Direct |
| Mar 20, 26 | Durkacz (Anthony John) 10% Security Holder of Issuer |
— | 100.00K | — | Direct |
| Mar 20, 26 | Saeed (Zeeshan) Director of Issuer |
BUY | 100.00K | $218.60K | Direct |
| Mar 12, 26 | Carroll (Donal) Director of Issuer |
EXERCISE | 14.80K | $31.05K | Direct |
| Mar 12, 26 | Durkacz (Anthony John) 10% Security Holder of Issuer |
— | 14.80K | — | Direct |
| Mar 12, 26 | Saeed (Zeeshan) Director of Issuer |
— | 14.80K | — | Direct |
| Dec 10, 25 | Durkacz (Anthony John) 10% Security Holder of Issuer |
BUY | 15 | $271 | Indirect |
| Dec 10, 25 | Saeed (Zeeshan) Director of Issuer |
BUY | 15 | $271 | Indirect |
| Nov 26, 25 | Carroll (Donal) Director of Issuer |
SELL | 6.97K | $68.42K | Direct |
| Nov 26, 25 | Carroll (Donal) Director of Issuer |
SELL | 500 | $4.74K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Carroll (Donal) |
Director of Issuer | 0 | Acquisition or disposition in the public market |
Durkacz (Anthony John) |
10% Security Holder of Issuer | 143.92K | Acquisition or disposition under a prospectus exemption |
Saeed (Zeeshan) |
Director of Issuer | 233.21K | Acquisition or disposition under a prospectus exemption |
Fundamentals
Market cap$19.74M
Enterprise value$20.24M
Revenue (TTM)—
Gross profit—
EBITDA$-11.78M
Net income$-25.16M
EPS (TTM)$-4.98
Free cash flow$-5.03M
Total cash$3.86M
Total debt$963.31K
Book value / share$1.05
Shares outstanding6.43M
Float7.63M
Short % of float3.24%
Dividend yield0.00%
Beta (5Y)0.38
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.39
PEG ratio—
Price / sales—
Price / book2.93
EV / revenue—
EV / EBITDA-1.72
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-621.46%
Return on assets-51.84%
Debt / equity15.81
Current ratio1.20
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $2.76M | $6.08M | $3.86M | $6.91M | -54.6% |
| Selling, general & admin | $12.01M | $9.31M | $13.20M | $15.98M | +29.0% |
| Total operating expense | $15.32M | $15.88M | $19.57M | $27.43M | -3.6% |
| Operating income | -$15.32M | -$15.88M | -$19.57M | -$27.43M | +3.6% |
| Net interest income | -$382.56K | $525.31K | $786.06K | $318.91K | -172.8% |
| Pre-tax income | -$26.96M | -$14.92M | -$18.23M | -$26.70M | -80.7% |
| Net income | -$26.18M | -$14.20M | -$17.90M | -$23.61M | -84.3% |
| Net income to common | -$26.18M | -$14.20M | -$17.90M | -$23.61M | -84.3% |
| Basic EPS | -8.20 | -13.12 | -29.93 | -39.61 | +37.5% |
| Diluted EPS | -8.20 | -13.12 | -29.93 | -39.61 | +37.5% |
| EBIT | -$26.34M | -$14.87M | -$18.23M | -$26.65M | -77.1% |
| EBITDA | -$25.79M | -$14.38M | -$15.72M | -$22.12M | -79.4% |
| Basic shares | 3.29M | 1.14M | 609.06K | 595.88K | +189.0% |
| Diluted shares | 3.29M | 1.14M | 609.06K | 595.88K | +189.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.91M | $6.00M | $2.76M | $16.98M | -68.2% |
| Cash & short-term investments | $2.36M | $7.20M | $3.51M | $17.00M | -67.2% |
| Inventory | $52.13K | $117.24K | $0 | — | -55.5% |
| Total current assets | $6.48M | $12.05M | $11.09M | $17.85M | -46.2% |
| Property, plant & equipment | $169.35K | $130.38K | $120.42K | $260.93K | +29.9% |
| Goodwill & intangibles | $4.51M | $4.93M | $5.36M | $12.04M | -8.5% |
| Total assets | $11.16M | $17.12M | $17.47M | $38.41M | -34.8% |
| Total current liabilities | $6.06M | $6.68M | $4.57M | $7.83M | -9.3% |
| Current debt | $1.77M | $771.14K | $300.55K | $300.55K | +129.9% |
| Total debt | $1.88M | $824.92K | $339.20K | $516.42K | +127.4% |
| Total liabilities | $6.06M | $6.68M | $4.57M | $7.87M | -9.3% |
| Retained earnings | -$198.29M | -$172.11M | -$157.91M | -$144.16M | -15.2% |
| Shareholder equity | $6.92M | $11.48M | $13.24M | $30.54M | -39.7% |
| Working capital | $420.06K | $5.37M | $6.52M | $10.02M | -92.2% |
| Net tangible assets | $2.41M | $6.55M | $7.88M | $18.50M | -63.2% |
| Shares issued | 3.89M | 2.30M | 605.80K | 592.37K | +69.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$26.96M | -$14.92M | -$18.23M | -$26.70M | — | -80.7% |
| Depreciation & amortisation | $545.78K | $490.57K | $2.51M | $4.53M | — | +11.3% |
| Stock-based compensation | $2.95M | $152.21K | $3.84M | $1.53M | — | +1,835.1% |
| Change in working capital | $1.99M | $9.76M | $1.64M | -$7.12M | — | -79.7% |
| Operating cash flow | -$8.24M | -$6.88M | -$10.83M | -$28.33M | — | -19.8% |
| Capital expenditure | — | — | — | -$363.96K | -$500.00K | — |
| Investing cash flow | -$1.95M | -$1.50M | -$269.58K | $12.12M | — | -29.9% |
| Share buybacks | $0 | $0 | -$2.96M | -$1.93M | — | — |
| Financing cash flow | $6.10M | $11.62M | -$3.13M | -$2.07M | — | -47.5% |
| Free cash flow | -$8.24M | -$6.88M | -$10.83M | -$28.70M | — | -19.8% |
| End cash position | $1.91M | $6.00M | $2.76M | $16.98M | — | -68.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $387.43K | $626.09K | $70.40K | $495.22K | $549.20K | — | -38.1% |
| Selling, general & admin | $1.77M | $2.16M | $2.16M | $4.02M | $4.22M | — | -18.1% |
| Total operating expense | $2.28M | $2.91M | $2.36M | $4.66M | $4.91M | — | -21.6% |
| Operating income | -$2.28M | -$2.91M | -$2.36M | -$4.66M | -$4.91M | — | +21.6% |
| Net interest income | -$239.16K | -$45.18K | $50.34K | -$4.66K | -$144.84K | — | -429.3% |
| Pre-tax income | -$3.09M | -$13.75M | -$3.70M | -$4.75M | -$9.77M | — | +77.5% |
| Net income | -$3.25M | -$13.56M | -$3.03M | -$5.32M | -$9.25M | — | +76.0% |
| Net income to common | -$3.25M | -$13.56M | -$3.03M | -$5.32M | -$9.25M | — | +76.0% |
| Basic EPS | -0.47 | -3.06 | — | -1.25 | -3.23 | -3.53 | +84.6% |
| Diluted EPS | -0.47 | -3.06 | — | -1.25 | -3.23 | -3.53 | +84.6% |
| EBIT | -$2.85M | -$13.71M | -$3.78M | -$4.64M | -$9.53M | — | +79.2% |
| EBITDA | -$2.73M | -$13.58M | -$3.65M | -$4.50M | -$9.39M | — | +79.9% |
| Basic shares | 6.65M | 4.49M | — | 3.80M | 3.02M | 2.47M | +48.2% |
| Diluted shares | 6.65M | 4.49M | — | 3.80M | 3.02M | 2.47M | +48.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.65M | $4.34M | $1.91M | $445.94K | $1.50M | -16.0% |
| Cash & short-term investments | $3.86M | $4.56M | $2.36M | $1.08M | $1.53M | -15.5% |
| Inventory | $53.01K | $51.47K | $52.13K | $77.62K | $76.87K | +3.0% |
| Total current assets | $9.96M | $10.37M | $6.48M | $9.34M | $10.34M | -3.9% |
| Property, plant & equipment | $125.89K | $147.54K | $169.35K | $190.75K | $228.17K | -14.7% |
| Goodwill & intangibles | $4.30M | $4.41M | $4.51M | $4.62M | $4.73M | -2.4% |
| Total assets | $14.39M | $14.93M | $11.16M | $14.15M | $15.30M | -3.6% |
| Total current liabilities | $8.30M | $16.35M | $6.06M | $6.65M | $13.25M | -49.2% |
| Current debt | $898.39K | $786.07K | $1.77M | $2.41M | $2.11M | +14.3% |
| Total debt | $963.31K | $870.06K | $1.88M | $2.56M | $2.27M | +10.7% |
| Total liabilities | $8.30M | $16.35M | $6.06M | $6.65M | $13.25M | -49.2% |
| Retained earnings | -$215.10M | -$211.85M | -$198.29M | -$195.26M | -$189.94M | -1.5% |
| Shareholder equity | $7.95M | $595.23K | $6.92M | $8.65M | $3.76M | +1,235.5% |
| Working capital | $1.66M | -$5.98M | $420.06K | $2.70M | -$2.91M | +127.8% |
| Net tangible assets | $3.64M | -$3.81M | $2.41M | $4.03M | -$961.51K | +195.6% |
| Shares issued | 7.58M | 5.86M | 3.89M | 3.82M | 3.47M | +29.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$3.09M | -$13.75M | -$3.70M | -$4.75M | -$9.77M | +77.5% |
| Depreciation & amortisation | $128.37K | $127.44K | $129.37K | $145.34K | $141.38K | +0.7% |
| Stock-based compensation | $13.45K | $892.06K | $808.45K | $996.19K | $849.58K | -98.5% |
| Change in working capital | $4.55M | -$3.30M | $652.18K | $2.13M | -$1.08M | +238.0% |
| Operating cash flow | -$1.79M | -$1.67M | -$305.60K | -$1.72M | -$1.95M | -7.2% |
| Investing cash flow | -$1.36M | -$2.89M | $350.65K | $408.42K | -$1.36M | +52.8% |
| Financing cash flow | $2.46M | $7.00M | $1.41M | $261.43K | $1.29M | -64.9% |
| Free cash flow | -$1.79M | -$1.67M | -$305.60K | -$1.72M | -$1.95M | -7.2% |
| End cash position | $3.65M | $4.34M | $1.91M | $445.94K | $1.50M | -16.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Mar 2026 | -0.68 | -4.17 | -509.4% |
| Sep 2025 | -3.70 | -1.77 | +52.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.59 | 1 | $0 | — |
| Next quarter | -0.70 | 1 | $0 | 0.0% |
| Current year | -2.58 | 1 | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target$12.24
High target$12.24
Low target$12.24
Implied upside298.62%
Analyst count1
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders8.40%
Held by institutions12.00%
Institutions holding28
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.55
-13.58% from price
SMA 20
3.56
-13.71% from price
SMA 50
3.37
-8.79% from price
SMA 100
3.88
-20.96% from price
SMA 200
4.33
-29.11% from price
EMA 12
3.43
-10.61% from price
EMA 26
3.47
-11.42% from price
EMA 50
3.49
-12.12% from price
RSI (14)
38.3
Neutral
MACD (12,26,9)
-0.03
Hist -0.09
ATR (14)
0.29
9.58% of price
Realised vol 30D
72.5%
Annualised
Bollinger upper
4.10
20, 2σ
Bollinger lower
3.01
20, 2σ
50 / 200 cross
Death
3.37 vs 4.33
Trend bias
Below 200
-29.11%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.49
Less volatile than market
Correlation to SPY
0.05
Largely independent
Realised vol 30D
72.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-87.8%
Peak to trough
Max drawdown 5Y
-98.4%
Peak to trough
ATR 14
0.29
9.58% of price
Beta (reported)
0.38
5Y monthly, from filing
Short interest
Shares short
242.50K
Prior 291.17K
Change vs prior
-16.7%
Shorts covering
% of float
3.24%
Normal
% of shares out
3.00%
Against total outstanding
Days to cover
1.1
Liquid
Float
7.63M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:65
Split dateAug 15, 2024
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-06
Corporate Changes & Voting Matters
6-K · 2026-09-24
Corporate Changes & Voting Matters
6-K · 2026-09-17
Corporate Changes & Voting Matters
6-K · 2026-09-15
Corporate Changes & Voting Matters
6-K/A · 2026-09-08
Corporate Changes & Voting Matters
6-K · 2026-09-02
Corporate Changes & Voting Matters
6-K · 2026-08-14
Corporate Changes & Voting Matters
6-K/A · 2026-08-13
Headlines
Quantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
NewMediaWire · 21h ago
Quantum BioPharma, Thermo Fisher Partner on Phase 2 Multiple Sclerosis Trial
MT Newswires · 1d ago
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
GlobeNewswire · 1d ago
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Benzinga · 1d ago
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
GlobeNewswire · 7d ago
Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing
NewMediaWire · 12d ago
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
GlobeNewswire · 13d ago
Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
NewMediaWire · 14d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.